Purpose
To evaluate the effect of dopaminergic medication and deep brain stimulation on ocular
function in Parkinson's disease (PD) and to measure vision-related quality of life
in subjects with PD.
Design
Prospective, comparative case series.
Participants and Controls
Twenty-seven PD and 16 control subjects were recruited.
Methods
Visual acuity, ocular motor function, convergence, and vision-related quality of life
using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) were
measured. Visual sensory and motor measurements were obtained during the on and off
states of PD dopaminergic treatment.
Main Outcome Measures
Convergence ability and vision-related quality of life.
Results
The PD subjects had a mean age of 58.8 years; 30% were female. Their mean duration
of PD was 10.9±6.8 years. The control subjects had a mean age of 61.6 years; 56% were
female. There was no difference in visual acuity, contrast sensitivity, or color vision
of the PD subjects in their on state compared with controls. Convergence amplitudes
measured with base-out prism were significantly poorer in PD subjects in their on
state compared with controls (24.1±8 Δ vs. 14.8 ±10.3 Δ;
P = 0.003). The mean composite VFQ-25 score was significantly worse in the PD subjects
compared with the controls (87.1±8.69 vs. 96.6±3.05;
P = 0.0001). Comparing the PD subjects in their on with their off states, there was
no difference in distance exodeviation, near exodeviation, or ocular ductions. Mean
convergence amplitudes and near point of convergence were better in the on state compared
with the off state: 14.8±10.3 Δ versus 10.7±9.0 Δ (
P = 0.0006) and 13.1±9.1 cm versus 18.1±12.2 cm (
P = 0.002), respectively.
Conclusions
Convergence ability is significantly poorer in PD subjects in both the on and off
states compared with controls, but improves significantly with systemic dopaminergic
treatment. Ocular motor function in PD subjects fluctuates in response to treatment,
which complicates ophthalmic management. Parkinson's disease subjects have a significant
reduction in vision-related quality of life, especially with near activities, that
is not associated with visual acuity.
Financial Disclosure(s)
The author(s) have no proprietary or commercial interest in any materials discussed
in this article.
References
- Movement disorders.Med Clin North Am. 2009; 93 (viii): 371-388
- Review of the visual system in Parkinson's disease.Optom Vis Sci. 1994; 72: 92-99
- Ophthalmologic features of Parkinson's disease.Neurology. 2004; 62: 177-180
- Ocular motility in Parkinson's disease.J Pediatr Ophthalmol Strabismus. 1996; 33: 144-147
- Visual dysfunction in Parkinson disease without dementia.Neurology. 2005; 65: 1907-1913
- Convergence insufficiency in idiopathic Parkinson's disease responsive to levodopa.Strabismus. 1999; 7: 169-174
- A randomized trial of deep-brain stimulation for Parkinson's disease.N Engl J Med. 2006; 355: 896-908
- Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.N Engl J Med. 1998; 339: 1105-1111
- Non-motor effects of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: preliminary physiological results.Neurol Sci. 2001; 22: 85-86
- Development of the 25-item National Eye Institute Visual Function Questionnaire.Arch Ophthalmol. 2001; 119: 1050-1058
- Parkinsonism: onset, progression and mortality.Neurology. 1967; 17: 427-442
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.Mov Disord. 2008; 23: 2129-2170
- A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol.Am J Ophthalmol. 2003; 135: 194-205
- The design of a new letter chart for measuring contrast sensitivity.Clin Vis Sci. 1988; 2: 187-199
- Quality improvement in neurology: AAN Parkinson disease quality measures.Neurology. 2010; 75: 2021-2027
- Measuring contrast sensitivity under different lighting conditions; comparison of three tests.Optom Vis Sci. 2006; 83: 290-298
- Normal values for the Pelli-Robson contrast sensitivity test.J Cataract Refract Surgery. 2001; 27: 261-266
Article Info
Publication History
Published online: September 29, 2011
Accepted:
June 28,
2011
Received in revised form:
May 27,
2011
Received:
March 1,
2011
Footnotes
Manuscript no. 2011-361.
Dr. Almer currently is with the Ophthalmology Department, Assaf Harofe Medical Center, Zeriffin, Israel. Dr. Marsh currently is with the Mental Health Care Line, Michael E. DeBakey Veterans Affairs Medical Center, and Departments of Psychiatry and Neurology, Baylor College of Medicine, Houston, Texas.
Supported by the National Institutes of Health , Bethesda, Maryland (grant no.: P50-NS-58377 [LM, MG]); subject recruitment was provided by the Morris K. Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins University, Baltimore, Maryland.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Identification
Copyright
© 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
